Webdisclosure.com

Search

SANOFI-AVENTIS (EPA:SAN) Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A

Directive transparence : information réglementée

02/03/2023 08:00